1. Home
  2. HIVE vs PRTA Comparison

HIVE vs PRTA Comparison

Compare HIVE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HIVE

HIVE Digital Technologies Ltd.

N/A

Current Price

$1.85

Market Cap

511.6M

Sector

N/A

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.26

Market Cap

501.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HIVE
PRTA
Founded
1987
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
511.6M
501.2M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
HIVE
PRTA
Price
$1.85
$9.26
Analyst Decision
Strong Buy
Buy
Analyst Count
8
9
Target Price
$6.75
$19.00
AVG Volume (30 Days)
8.5M
483.6K
Earning Date
02-17-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
$169.51
$1,111.38
Revenue Next Year
$39.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$4.32
52 Week High
$7.84
$12.71

Technical Indicators

Market Signals
Indicator
HIVE
PRTA
Relative Strength Index (RSI) 36.39 51.33
Support Level $1.60 $9.07
Resistance Level $2.33 $9.59
Average True Range (ATR) 0.11 0.39
MACD -0.00 0.02
Stochastic Oscillator 4.31 45.85

Price Performance

Historical Comparison
HIVE
PRTA

About HIVE HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: